Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcript
Atossa Therapeutics, Inc. recently discussed the challenges faced in breast cancer drug development during a conference call. The company highlighted its lead program, (Z)-endoxifen, and its potential benefits for patients. The conversation included insights from industry experts on innovation in clinical research.
- ▪Atossa Therapeutics, Inc. is focused on developing treatments for breast cancer.
- ▪The company's lead program is (Z)-endoxifen, which aims to benefit breast cancer patients.
- ▪The discussion featured insights from Dr. Laura Esserman from UCSF and CEO Steven Quay.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906725-atossa-therapeutics-inc-atos-discusses-challenges-in-breast-cancer-drug-development-and"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
